Divalproex sodium (DVX) is used in correctional settings to treat impulsive aggression and mood lability in patients without comorbid bipolar disorder. This review of DVX use in the Connecticut Department of Correction examined the psychiatric diagnostic impression of patients prescribed DVX, the doses used, and the symptomatic and functional change over time. Clinical charts of 168 offenders treated with DVX for one or more months were randomly selected for clinical outcome review and were divided into subgroups based on clinical impression for DVX prescription. In participants without bipolar disorder (44.6%), DVX was used to target impulsivity (14.3%) and mood lability (17.3%). Clinical improvement was noted in bipolar and nonbipolar groups (p < .001). The impulsive/aggressive subgroup was the only nonbipolar subgroup in which DVX yielded clinical benefit. This symptom-driven use of DVX is associated with clinical improvement when impulsive aggression is the target symptom.
Afaq, I., Riaz, J., Sedky, K., Chung, D.J., Vanina, Y., el-Mallakh, R., et al. (2002). Divalproex as a calmative adjunct for aggressive schizophrenic patients. Journal of the Kentucky Medical Association , 100(1), 17-22.
2.
Alderfer, B.S., & Allen, M.H. (2003). Treatment of agitation in bipolar disorder across the life cycle. Journal of Clinical Psychiatry,64(Suppl . 4), 3-9.
3.
Blackburn, R., & Coid, J.W. (1999). Empirical clusters of DSM-III personality disorders in violent offenders. Journal of Personality Disorders, 13, 18-34.
4.
Blake, P., & Grafman J. (2004). The neurobiology of aggression. Lancet, 364(Suppl. 1), 12-13.
5.
Bowden, C.L., Janicak, P.G., Orsulak, P., Swann, A.C., Davis, J.M., Calabrese J.R., et al. (1996). Relation of serum valproate concentration to response in mania. American Journal of Psychiatry, 153(6), 765-770.
6.
Bureau of Justice Statistics. (2005). Probation and parole in the United States, 2004 (Bulletin No. NCJ 210676) . Washington, DC: U.S. Department of Justice, Office of Justice Programs.
7.
Casey, D.E., Daniel, D.G., Wassef, A.A., Tracey, L.A., Wozniak, P., & Sommerville, K.W. (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia . Neuropsychopharmacology, 28(11), 2052-2053.
8.
Coid, J.W. (2002). Personality disorders in prisoners and their motivation for dangerous and disruptive behavior. Criminal Behaviour and Mental Health, 12(3), 209-226.
9.
Davis, L.L., Ryan, W., Adinoff, B., & Petty, F. (2000). Comprehensive review of the psychiatric uses of valproate. Journal of Clinical Psychopharmacology, 20(1,Suppl.1), 1S-17S.
10.
deAlmeida, R.M., Ferrari, P.F., Parmigiani, S., & Miczek, K.A. (2005). Escalated aggressive behavior: Dopamine, serotonin, and GABA. European Journal of Pharmacology, 526(1-3), 51-64.
11.
DeJong, J., Virkkunen, M., & Linnoila, M. (1992). Factors associated with recidivism in a criminal population. Journal of Nervous and Mental Disease, 80(9), 543-550.
12.
Ditton, P.M. (1999). Bureau of Justice Statistics, special report, mental health and treatment of inmates and probationers (NCJ Publication No. 174469). Washington, DC: U.S. Department of Justice.
13.
Frankenburg, F.R., & Zanarini, M.C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry , 63(5), 442-446.
14.
Gobbi, G., & Janiri, L. (2006). Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology, 85(2), 255-262.
15.
Goedhard, L.E., Stolker, J.J., Heerdink, E.R., Nijman, H.L., Olivier, B., & Egberts, T.C. (2006). Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review. Journal of Clinical Psychiatry, 67(7), 1013-1024.
16.
Hodgins, S. (2001). The major mental disorders and crime: Stop debating and start treating and preventing. International Journal of Law and Psychiatry, 24(4-5), 427-446.
17.
Hollander, E., Allen, A., Lopez-Prietro, R., Bienstock, C.A., Grossman, R., Siever, L.J., et al. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62(3), 199-203.
18.
Hollander, E., & Evers, M. (2001). New developments in impulsivity. Lancet, 358(9286), 949-950.
19.
Hollander, E., Swann, A.C., Coccaro, E.F., Jiang, P., & Smith, T.B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162(3), 621-624.
20.
Hollander, E., Tracy, K.A., Swann, A.C., Coccaro, E.F., McElroy, S.L., Wozniak, P., et al. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in Cluster B personality disorders. Neuropsychopharmacology, 28(6), 1186-1197.
21.
Honack, D., Wahnschaffe, U., & Loscher, W. (1991). Kindling from stimulation of a highly sensitive locus in the posterior part of the piriform cortex. Comparison with amygdala kindling and effects of antiepileptic drugs. Brain Research , 538(2), 196-202.
22.
Kavoussi, R.J., & Coccaro, E.F. (1998). Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Journal of Clinical Psychiatry, 59(12), 676-680.
23.
Lamb, H., & Weinberger, L. (1998). Persons with severe mental illnesses in jails and prisons: A review. Psychiatric Services , 49, 483-492.
24.
Lindenmayer, J.P., & Kotsaftis, A. (2000). Use of sodium valproate in violent and aggressive behaviors: A critical review. Journal of Clinical Psychiatry , 61(2), 123-128.
25.
McAllister-Williams, R.H. (2006). Relapse prevention in bipolar disorder: A critical review of current guidelines. Journal of Psychopharmacology , 20(2, Suppl.), 12-16.
26.
Revicki, D.A., Paramore, L.C., Sommerville, K.W., Swann, A.C., & Zajacka, J.M. (2003). Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: Health-related quality of life and medical cost outcomes. Journal of Clinical Psychiatry, 64(3), 288-294.
27.
Robins, L.N., & Regier, D.A. (1991). Psychiatric disorders in America: The Epidemiologic Catchment Area Study. New York: Free Press.
28.
Sentencing Project. (2002, January). Mentally ill offenders in the criminal justice system: An analysis and prescription . Retrieved August 1, 2007, from http://www.soros.org/initiatives/justice/articles_publications/publications/mi_offenders_20020101
29.
Swanson, J., Estroff, S., Swartz, M., Borum, R., Lachicotte, W., Zimmer, C., et al. (1997). Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry, 60, 1-22.
30.
Teplin, L.A. (1994). Psychiatric and substance abuse disorders among male urban jail detainees. American Journal of Public Health , 84(2), 290-293.
31.
Teplin, L.A., Abram, K.M., & McClelland, G.M. (1996). Prevalence of psychiatric disorders among incarcerated women. I. Pretrial jail detainees. Archives of General Psychiatry, 53(6), 505-512.
32.
Trestman, R.L. (2000). Behind bars: Personality disorders. Journal of the American Academy of Psychiatry and the Law, 28(2), 232-235.
33.
Wang, E.W., & Diamond, P.M. (1999). Empirically identifying factors related to violence risk in corrections. Behavioral Sciences & the Law, 17(3), 377-389.
34.
Wilcox, J. (1994). Divalproex sodium in the treatment of aggressive behavior. Annals of Clinical Psychiatry, 6(1), 17-20.
